References
- Sawyers C L. Chronic myeloid leukemia. N Engl J Med 1999; 340: 130–134
- Talpaz M, Silver R T, Druker B J, Goldman J M. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937
- Melo J V. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375–2384
- Deininger M, Goldman J, Melo J. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–3356
- Druker B J, Tamura S, Buchdunger E, Ohno S, Segal G M, Fanning S, et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 1996; 2: 561–566
- O'Brien S G, Francois G, Larson R A, Insa G, Michele B, Francisco C. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
- Kantarjian H M, Cortes J E, O'Brien S, Luthra R, Giles F, Verstovsek S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia after failure of interferon. Blood 2004; 104: 1979–1988
- Cortes J, O'Brien S, Kantarjian H M. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204–2205
- Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lassarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005; 90: 979–981
- Breccia M, Diverio D, Pane F, Nanni M, Russo E, Biondo F, et al. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph+ CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. Leuk Res 2006; 30: 1577–1579
- Micheal J M, Brian J D, Richard T M. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004; 28: 71–73
- Rousselot P, Huguet F, Rea D, Legros L, Cayuela J M, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2006; 109: 58–60
- Verma D, Kantarjian H, Jain N, Cortes J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon α. Leuk Lymphoma 2008; 49: 1399–1402
- Goldman J M. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110: 2828–2837
- Hochhaus A, Druker B J, Larson R A, O'Brien S G, Gathmann I, Guilhot F. IRIS 6-Yeay follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2007; 110: 15a–16a, Abstract 25
- Graham S M, Jørgensen H G, Allan E, Pearson C, Alcorn M J, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–325